NCT02393248 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT02393248
Title	Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Recruitment	Terminated
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Incyte Corporation
Indications	endometrial cancer lung squamous cell carcinoma cholangiocarcinoma myeloproliferative neoplasm multiple myeloma transitional cell carcinoma breast cancer Advanced Solid Tumor stomach cancer
Therapies	Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab
Age Groups:	adult
Covered Countries	USA \| DNK

Additional content available in CKB BOOST